HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for a private investment in public equity financing (the "PIPE"), which is expecte

GENEVA, June 27, 2026 /PRNewswire/ -- Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of developing dementia than those who do not, according to new research presented at the European Academy of Neurology (EAN) Congress 2026. Hearing loss is widely recognised as the largest modifiable risk factor for dementia. Yet whether hearing aids can reduce dementia risk remains debated. To explore this, researchers from University Hospital Zurich and the Universit

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syringe to support weight-based dosing for those patients weighing less than 40 kg SKYRIZI becomes the first and only IL-23 inhibitor approved in the U.S. for pediatric patients six years of age and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis NORTH CHICAGO, Ill., June 2

SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 20,500 shares of its common stock and 3,900 restricted stock units (RSUs) to seven newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used

STOCKHOLM, June 26, 2026 /PRNewswire/ -- The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical safety or efficacy concerns were identified that impact approvability Sobi to meet with FDA to discuss next steps for resubmission Sobi® (STO: SOBI) today announced that the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Appli

WILMINGTON, NC, UNITED STATES, June 26, 2026 / EINPresswire.com / -- FOR IMMEDIATE RELEASE Breaking Barriers to Substance Use Recovery, (“BBSUR”), a non-profit coalition dedicated to bringing innovative opioid treatment options to communities with unmet medical need, fully endorses Reps. Deborah Ross, Don Davis, and Carol Miller’s amendment to the FY27 National Defense Authorization Act, amendment #1238, that expands access to virtual-based opioid treatment for veterans. BBSUR was formed to prom

CHAPEL HILL, N.C., June 26, 2026 /PRNewswire/ -- Ahead of International Neonatal Screening Day on June 28, MiracleFeet, a global nonprofit providing access to clubfoot treatment and a member of the Global Action for Congenital Conditions (GACC), welcomes the launch of the World Health Organization's (WHO) new report: Strengthening capacity for newborn screening, diagnosis and management of birth defects. The report provides guidance, especially for low- and middle-income countries (LMICs), to bu

NEW YORK--(BUSINESS WIRE)--Researchers at Hospital for Special Surgery (HSS) have uncovered a critical link between the immune system in early life and its function in adulthood. The study, published in Science Immunology, identifies a new role for specialized skin immune cells, called Langerhans cells, in shaping the development of lymphatic vessels—an essential part of the body’s immune network. Lymphatic vessels act as communication highways, carrying signals from tissues to the immune system

Chicago longevity medicine clinic highlights three cardiovascular tests that can uncover hidden heart disease risk missed by routine blood work. Our goal is to identify hidden risk years before someone experiences a heart attack or stroke. Prevention is most effective when we have the complete picture.” — Rahul Khare, MD CHICAGO, IL, UNITED STATES, June 26, 2026 / EINPresswire.com / -- Heart disease remains the leading cause of death in the United States, yet many heart attacks occur in people w

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including those early in their disease, participants with lower symptom burden and those who experienced common infections To address an important evidence gap, the PETUNIAc study design will be presented – demonstrating the innovative way pregnancy outcomes data will be collected following treatment with IMAAVY IMAAVY, an immunoselect